A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients

A phase I, open-label, multicenter study of cediranib and AZD0530 in patients with advanced solid tumors

(2017) T. Trarbach et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)

(2013) Y. Loriot et al.   ANNALS OF ONCOLOGY

A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy

(2013) Przemyslaw W. Twardowski et al.   ANTI-CANCER DRUGS

Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer

(2013) William L. Dahut et al.   BJU INTERNATIONAL

A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)

(2013) S Sahebjam et al.   BRITISH JOURNAL OF CANCER

Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies

(2013) Jane Kendrew et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium

(2013) Srikala S. Sridhar et al.   INVESTIGATIONAL NEW DRUGS

Src kinases mediate VEGFR2 transactivation by the osteostatin domain of PTHrP to modulate osteoblastic function

(2013) Adela García-Martín et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial

(2013) Ian F Tannock et al.   LANCET ONCOLOGY

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

(2013) C. Parker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel

(2013) John Araujo et al.   Cancer Management and Research

Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study

(2012) Peter Mulders et al.   EUROPEAN JOURNAL OF CANCER

Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401

(2012) William Kevin Kelly et al.   JOURNAL OF CLINICAL ONCOLOGY

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

(2012) Karim Fizazi et al.   LANCET ONCOLOGY

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

(2012) Charles J. Ryan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects

(2012) Antonio Garcia-Gomez et al.   PLoS One

Exploration of acridine scaffold as a potentially interesting scaffold for discovering novel multi-target VEGFR-2 and Src kinase inhibitors

(2011) Xudong Luan et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

(2011) H. M. Kantarjian et al.   BLOOD

Dasatinib combined with docetaxel for castration-resistant prostate cancer

(2011) John C. Araujo et al.   CANCER

Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-induced osteoclast formation

(2011) John C. Araujo et al.   CANCER BIOLOGY & THERAPY

Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells

(2011) Lori Rice et al.   CLINICAL & EXPERIMENTAL METASTASIS

Inhibition of Prostate Cancer Osteoblastic Progression with VEGF121/rGel, a Single Agent Targeting Osteoblasts, Osteoclasts, and Tumor Neovasculature

(2011) K. A. Mohamedali et al.   CLINICAL CANCER RESEARCH

Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours

(2011) Tanja Trarbach et al.   INVESTIGATIONAL NEW DRUGS

Molecular mechanisms and clinical applications of angiogenesis

(2011) Peter Carmeliet et al.   NATURE

Cediranib inhibits both the intraosseous growth of PDGF D-Positive prostate cancer cells and the associated bone reaction

(2011) Abdo J. Najy et al.   PROSTATE

Once-daily Dasatinib: Expansion of Phase II Study Evaluating Safety and Efficacy of Dasatinib in Patients With Metastatic Castration-resistant Prostate Cancer

(2011) Evan Y. Yu et al.   UROLOGY

The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts

(2010) Hichame Id Boufker et al.   BMC CANCER

A Novel Signaling Axis of Matriptase/PDGF-D/ -PDGFR in Human Prostate Cancer

(2010) C. V. Ustach et al.   CANCER RESEARCH

Cediranib/AZD2171 Inhibits Bone and Brain Metastasis in a Preclinical Model of Advanced Prostate Cancer

(2010) J. J. Yin et al.   CANCER RESEARCH

Invasive Prostate Carcinoma Driven by c-Src and Androgen Receptor Synergy

(2010) H. Cai et al.   CANCER RESEARCH

The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo

(2010) Kate Vandyke et al.   JOURNAL OF BONE AND MINERAL RESEARCH

A novel intracellular isoform of VEGFR-1 activates Src and promotes cell invasion in MDA-MB-231 breast cancer cells

(2010) Belén Mezquita et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

Effect of the Specific Src Family Kinase Inhibitor Saracatinib on Osteolytic Lesions Using the PC-3 Bone Model

(2010) J. C. Yang et al.   MOLECULAR CANCER THERAPEUTICS

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts

(2010) Y-C Lee et al.   ONCOGENE

Proliferation of Immature Tumor Vessels Is a Novel Marker of Clinical Progression in Prostate Cancer

(2009) K. Gravdal et al.   CANCER RESEARCH

Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer

(2009) E. Y. Yu et al.   CLINICAL CANCER RESEARCH

Genomic Strategy for Targeting Therapy in Castration-Resistant Prostate Cancer

(2009) Prateek Mendiratta et al.   JOURNAL OF CLINICAL ONCOLOGY

An open-label, Phase I study of cediranib (RECENTIN™) in patients with acute myeloid leukemia

(2009) Walter Fiedler et al.   LEUKEMIA RESEARCH

Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines

(2009) M. P. Morelli et al.   MOLECULAR CANCER THERAPEUTICS

Targeting Src Family Kinases Inhibits Growth and Lymph Node Metastases of Prostate Cancer in an Orthotopic Nude Mouse Model

(2008) S. I. Park et al.   CANCER RESEARCH

Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study

(2008) D. R. Berthold et al.   CLINICAL CANCER RESEARCH

The dual role of IL-6-type cytokines on bone remodeling and bone tumors

(2008) Frédéric Blanchard et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Angiopoietin-1 Prevents VEGF-Induced Endothelial Permeability by Sequestering Src through mDia

(2008) Julie Gavard et al.   DEVELOPMENTAL CELL

Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group

(2008) Scott A. Laurie et al.   JOURNAL OF CLINICAL ONCOLOGY

Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

(2008) Dominik R. Berthold et al.   JOURNAL OF CLINICAL ONCOLOGY

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis

(2008) K Vandyke et al.   LEUKEMIA

The Tyrosine Kinase Activity of c-Src Regulates Actin Dynamics and Organization of Podosomes in Osteoclasts

(2007) Olivier Destaing et al.   MOLECULAR BIOLOGY OF THE CELL